

PRESS RELEASE
3rd February 2026



Cherry Biotech enters partnership with Cytion under a partnership agreement on Cytion 800+ Cell Line catalog.

Montreuil, France, 3rd February 2026: Cherry Biotech, a French company specializing in organ-on-chip and organoid technologies for biomedical research announced today it has entered a licensing agreement with Cytion, a leading cell bank, specializing in providing high-quality, contamination-free cells from both human and animal origins. With an extensive catalog of over 800 cell lines, our diverse collection ensures to have the right cells to meet the specific demands for research projects.


The partnership agreement is to open access to Cytion's cell line catalog to Cherry Biotech product development. This partnership will allow the production of organoids with a high degree of human physiological relevancy and therefore contribute to the generation of real-life-like data by our customers during preclinical drug development phases.

Cherry Biotech's *in vitro* product range combine AI analysis, high-resolution live imaging and precisely controlled organoid culture to better predict the efficacy and safety of drugs, generating real life-like preclinical data. Access to Cytion cell line catalog is key for the development of our latest product, ready to use organoids in a standard multiwell plate: the organoidPlate. Available for adipose tissue, breast cancer and lung this multiwell plate, Cytion's cells are stepping up the physiological relevance of our models.

Jonathan Steubing, CEO, Cytion, commented: *"Cherry Biotech is building an impressive platform that bridges advanced organoid culture with quantitative imaging and AI-based interpretation. We are delighted to partner with them and to provide authenticated, contamination-free cell lines as the reliable starting material for their organoid models. Together, we aim to empower customers with ready-to-use organoid solutions, enabling more realistic preclinical data generation and better-informed decisions in drug development."*

Pierre Gaudriault, Chief Business Development Officer, Cherry Biotech, added: *"Partnering with Cytion is key to unlock the generation of real-life-like dataset by our customers, and to support their decision-making during drug development. Cytion's product quality and reliability is a critical asset in our daily activity, and I am really thrilled to have entered this partnership agreement with them."*

ENDS

Notes to Editors:

*Jonathan Steubing,
CEO, Cytion*

*Pierre Gaudriault, Chief Business
Development Officer, Cherry
Biotech*

*Cherry Biotech's 3D Human
Breast Cancer Organoid from
Cherry Biotech CanceroPlate*

For further information, please contact:

Pierre Gaudriault
Cherry Biotech
Email: pierre.gaudriault@cherrybiotech.com

About Cherry Biotech www.cherrybiotech.com

Cherry Biotech is a French company that develops products and expertise in complex 3D cell culture, like organoids or organ on chip. The product portfolio of Cherry Biotech aimed at helping researchers in pharma, academia and CRO to generate real life like preclinical data during for drug discovery and personalised medicine. Its mission is to replace animal wherever possible by providing human physiology mimicking in vitro models.

Among its noticeable products, the OrganoidPlate provide its user with a standard multiwell plate loaded with ready to use mature and differentiated organoids. Saving up to 3 weeks in culture time, allowing the user to focus on the data generation.

In addition, Cherry Biotech's CUBIX platform enables pharmaceutical, biotech companies and healthcare providers to recreate immunocompetent human vascularized organ models and tumor microenvironments for better evaluation of their drug candidates.

By enabling the reconstruction of human 3D models that mimic human physiology and pathophysiology over several weeks, Cherry Biotech's proprietary CUBIX technology is the only solution that can convert a standard 2D multi-well plate into a 3D cell culture (Organ on Well).

About Cytion <https://www.cytion.com/>

As a leading cell bank, we specialize in providing high-quality, contamination-free cells from both human and animal origins. Our rigorous quality control and authentication processes ensure that researchers and scientists can rely on our cell lines for their genetic authenticity and reliability.

Cytion offers an extensive catalog of over 1000 cell lines, including well-known lines such as HeLa, HEK293, HaCaT, and many more. Our diverse collection ensures that we have the right cells to meet the specific demands of your research projects. Each cell line is third-party authenticated and quality-controlled to provide you with the highest level of reliability and reproducibility. Our comprehensive services include assay ready cells, cell

expansion, and sample storage, all designed to support the growing needs of your research projects. We provide large quantities of high-quality cells and pre-prepared assay ready cells, enabling you to expedite your research with cells that are ready to use immediately upon arrival.

With Cytion, experience the ease and confidence in sourcing authentic cell culture solutions. Join the many researchers who trust Cytion for their cellular research needs. Discover the difference that quality and reliability make in your scientific endeavors. Connect with us to learn more about how Cytion can support your research and development goals.